Eyal Rubin
2019
In 2019, Eyal Rubin earned a total compensation of $154.2K as Senior Vice President, Chief Financial Officer at Protalix BioTherapeutics.
Compensation breakdown
| Option Awards | $20,468 |
|---|---|
| Salary | $81,521 |
| Stock Awards | $25,000 |
| Other | $27,217 |
| Total | $154,206 |
Rubin received $81.5K in salary, accounting for 53% of the total pay in 2019.
Rubin also received $20.5K in option awards, $25K in stock awards and $27.2K in other compensation.
Rankings
In 2019, Eyal Rubin's compensation ranked 13,633rd out of 13,971 executives tracked by ExecPay. In other words, Rubin earned more than 2.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 13,633 out of 13,971 | 2nd |
Division Manufacturing | 5,551 out of 5,695 | 3rd |
Major group Chemicals And Allied Products | 2,153 out of 2,194 | 2nd |
Industry group Drugs | 1,845 out of 1,880 | 2nd |
Industry Biological Products, Except Diagnostic Substances | 385 out of 389 | 1st |
Source: SEC filing on April 15, 2020.
Rubin's colleagues
We found six more compensation records of executives who worked with Eyal Rubin at Protalix BioTherapeutics in 2019.
2019
Moshe Manor
Protalix BioTherapeutics
Chief Executive Officer
2019
Yoseph Shaaltiel
Protalix BioTherapeutics
Executive Vice President, Research and Development
2019
Einat Almon
Protalix BioTherapeutics
Senior Vice President, Product Development
2019
Dror Bashan
Protalix BioTherapeutics
Chief Executive Officer
2019
Yaron Naos
Protalix BioTherapeutics
Senior Vice President, Operations
2019
Yossi Maimon
Protalix BioTherapeutics
Chief Financial Officer
News
Protalix BioTherapeutics CEO Dror Bashan's 2023 pay jumps 83% to $2.7M
April 29, 2024
Protalix BioTherapeutics CEO Dror Bashan's 2022 pay jumps 27% to $1.5M
May 18, 2023
Protalix BioTherapeutics CEO Dror Bashan's 2021 pay slips 14% to $1.2M
April 29, 2022
Protalix BioTherapeutics CEO Moshe Manor's 2019 pay slips 14% to $616K
April 15, 2020